ATTR Amyloidosis

ATTR amyloidosis is a serious, progressive disease caused by the misfolding and accumulation of transthyretin protein in tissues and organs throughout the body. Early recognition and targeted treatment are critical for slowing disease progression and improving patient outcomes.

Key Takeaways

• ATTR amyloidosis occurs when transthyretin (TTR) protein misfolds and deposits as amyloid fibrils in organs such as the heart and peripheral nerves.
• The disease has two main forms: hereditary (caused by a genetic mutation) and wild-type (associated with aging).
• FDA-approved therapies include TTR stabilizers and RNA-based silencers that reduce or halt amyloid production.
• Early diagnosis significantly improves prognosis, as the disease can remain undetected for years due to nonspecific symptoms.
• Treatment strategies differ meaningfully between hereditary and wild-type forms, requiring individualized medical evaluation.

Transthyretin Amyloidosis: Symptoms, Types, and Diagnosis

Transthyretin amyloidosis (ATTR amyloidosis) refers to a systemic condition in which the transthyretin protein—normally produced by the liver—becomes unstable, misfolds, and aggregates into amyloid fibrils that deposit in organs and tissues. These deposits disrupt normal organ function, most critically affecting the heart and peripheral nervous system. The disease affects an estimated 50,000 people worldwide with hereditary forms, while wild-type ATTR amyloidosis may affect a considerably larger population of older adults, though exact prevalence remains underdiagnosed.

Symptoms vary depending on which organs are predominantly affected. Cardiac involvement typically presents as shortness of breath, fatigue, and signs of heart failure, while peripheral nerve involvement leads to numbness, tingling, pain, or weakness in the limbs—a pattern known as peripheral neuropathy. Autonomic dysfunction, including orthostatic hypotension and gastrointestinal disturbances, is also common. Because these symptoms overlap with many other conditions, diagnosis is frequently delayed by several years after symptom onset.

Diagnosing ATTR amyloidosis requires a combination of clinical evaluation, imaging, and tissue confirmation. Technetium-pyrophosphate (Tc-PYP) scintigraphy has emerged as a non-invasive imaging tool with high sensitivity for cardiac ATTR amyloidosis. Genetic testing is essential to distinguish between hereditary and wild-type forms. Tissue biopsy with Congo red staining, which reveals apple-green birefringence under polarized light, remains the gold standard for amyloid confirmation. Echocardiography may reveal a characteristic pattern of increased wall thickness and impaired diastolic function, raising clinical suspicion.

ATTR Amyloidosis Treatment Options: Medications and Therapies

The landscape of ATTR amyloidosis treatment options has advanced substantially over the past decade, shifting from purely supportive care to disease-modifying therapies. These treatments fall into two broad mechanistic categories: TTR stabilizers, which prevent the protein from misfoldingand dissociating, and TTR silencers, which reduce TTR production at the genetic level.

Tafamidis, an FDA-approved TTR stabilizer, has demonstrated significant reductions in cardiovascular mortality and hospitalizations in patients with ATTR cardiomyopathy. In the pivotal ATTR-ACT trial, tafamidis reduced all-cause mortality by 30% compared to placebo over 30 months. Another stabilizer, diflunisal, is used off-label in some clinical settings. Patisiran and inotersen represent RNA-based therapies—patisiran is a small interfering RNA (siRNA) agent, and inotersen is an antisense oligonucleotide (ASO)—both of which have demonstrated efficacy in hereditary ATTR amyloidosis with polyneuropathy.

Newer ATTR amyloidosis medications and therapies continue to emerge from clinical research. Vutrisiran, a next-generation siRNA therapy administered quarterly, has received FDA approval and shown improved tolerability compared to earlier agents. Eplontersen, another ASO-based therapy, has also received regulatory approval for hereditary transthyretin-mediated amyloid polyneuropathy. Supportive management—including diuretics for fluid management, antiarrhythmic therapy, and pacemaker implantation for conduction abnormalities—remains an important adjunct. Patients with severe cardiac disease may be evaluated for heart transplantation in select cases.

Among the latest treatments for transthyretin amyloidosis, researchers are also investigating amyloid fibril disruptors—agents designed to break down existing amyloid deposits rather than merely preventing new ones. These investigational compounds, including antibody-based therapies such as NI006, represent a potential next frontier in reversing rather than stabilizing the disease. Clinical trials are ongoing, and patients with ATTR amyloidosis are encouraged to discuss eligibility with their treating physicians.

Hereditary vs. Wild-Type ATTR Amyloidosis: How Treatment Differs

Hereditary vs. wild-type ATTR amyloidosis treatment strategies differ based on underlying disease biology, age of onset, and organ involvement patterns. Hereditary ATTR amyloidosis (hATTR) results from a pathogenic variant in the TTR gene, with more than 130 mutations identified worldwide. The Val30Met mutation is among the most common globally, while the Val122Ile variant disproportionately affects individuals of West African descent, appearing in approximately 3–4% of African Americans according to data from the American Heart Association.

In hereditary disease, polyneuropathy is often a dominant feature alongside or preceding cardiac involvement, making RNA-targeting therapies such as patisiran and vutrisiran particularly relevant. Liver transplantation was historically used for hATTR, as the liver is the primary source of mutant TTR production; however, it has largely been superseded by the newer pharmacological agents that offer comparable or superior efficacy without the risks of transplantation. Genetic counseling is an integral component of managing hereditary ATTR amyloidosis, given the autosomal dominant inheritance pattern and implications for family members.

Wild-type ATTR amyloidosis (wtATTR), previously called senile systemic amyloidosis, occurs without a genetic mutation and is predominantly a disease of older men, typically presenting after the age of 65. Cardiac involvement is the hallmark, and cardiomyopathy is almost universally present. Tafamidis is the cornerstone treatment for wild-type disease, given the predominance of cardiac manifestations. Because wtATTR patients are generally older and may have multiple comorbidities, treatment decisions must carefully account for overall health status, kidney and liver function, and medication tolerability.

Disease Progression and Prognosis in ATTR Amyloidosis

ATTR amyloidosis disease progression and prognosis depend on multiple factors, including the disease subtype, the specific TTR mutation (in hereditary cases), the stage at diagnosis, and the organs involved. Untreated, the disease follows a relentlessly progressive course. In patients with ATTR cardiomyopathy, median survival without treatment has historically been estimated at two to six years following diagnosis, depending on disease stage. Neurological forms may progress more slowly but still result in significant disability.

Disease staging systems have been developed to help predict outcomes and guide treatment intensity. For cardiac ATTR amyloidosis, the Mayo Clinic staging system uses biomarkers such as N-terminal pro–B-type natriuretic peptide (NT-proBNP) and troponin T to stratify patients into three prognostic stages. Patients diagnosed at an earlier stage—before significant myocardial damage—derive the greatest benefit from TTR-targeted therapies. This underscores the urgency of timely diagnosis, particularly in patients presenting with unexplained heart failure with preserved ejection fraction.

With the advent of effective disease-modifying therapies, the prognosis for ATTR amyloidosis is improving meaningfully. Clinical trial data demonstrate that tafamidis-treated patients experienced sustained reductions in mortality and functional decline compared to untreated controls. RNA-silencing agents have shown stabilization and, in some cases, modest neurological improvement in polyneuropathy patients. Regular monitoring—including echocardiography, biomarker assessment, and neurological evaluation—is essential for tracking disease trajectory and adjusting treatment as the disease evolves. Long-term outcomes data continue to accumulate as newer therapies enter routine clinical practice.

Frequently Asked Questions

Is ATTR amyloidosis hereditary?

ATTR amyloidosis exists in both hereditary and wild-type forms. The hereditary form is caused by a mutation in the TTR gene and follows an autosomal dominant inheritance pattern, meaning a parent with the mutation has a 50% chance of passing it to each child. The wild-type form is not inherited—it develops due to age-related instability of normal TTR protein and occurs primarily in older adults, particularly men over 65. Genetic testing can definitively distinguish between the two forms.

Can ATTR amyloidosis be cured?

Currently, there is no definitive cure for ATTR amyloidosis, but FDA-approved therapies can significantly slow or stabilize disease progression. TTR stabilizers such as tafamidis reduce cardiovascular mortality, while RNA-silencing agents reduce TTR production and can halt neuropathy progression. Liver transplantation was historically curative for the liver’s contribution to mutant TTR production in hereditary disease, though it is less commonly performed today given effective drug alternatives. Ongoing research into amyloid-clearing antibodies may offer future curative potential.

How is ATTR amyloidosis different from AL amyloidosis?

ATTR amyloidosis and AL amyloidosis are both systemic amyloid diseases but have distinct causes and treatments. ATTR amyloidosis involves misfolded transthyretin protein, while AL amyloidosis is driven by abnormal immunoglobulin light chains produced by clonal plasma cells, often in the context of a plasma cell disorder. Their organ involvement patterns can overlap, particularly in the heart, but treatment approaches differ entirely—AL amyloidosis is treated with chemotherapy or stem cell transplantation, whereas ATTR amyloidosis is managed with TTR-targeted agents. Accurate typing is essential for appropriate management.